Self-Assembled Nanomicelles of Affibody-Drug Conjugate with Excellent Therapeutic Property to Cure Ovary and Breast Cancers

• DOI: 10.1007/s40820-021-00762-9
• Publication Date: 2021-12-13T09:02:33Z
• Authors: Xuelin Xia; Xiaoyuan Yang; Wei Huang; Xiaoxia Xia; Deyue Yan
• Keywords: Conjugate; Targeted Therapy

Affibody molecules are small non-immunoglobulin affinity proteins, which can precisely target to some cancer cells with specific overexpressed molecular signatures. However, the relatively short in vivo half-life of them seriously limited their application drug targeted delivery for therapy. Here an amphiphilic affibody-drug conjugate is self-assembled into nanomicelles prolong circulation time As example concept, nanoagent was prepared through self-assembly ZHER2:342-Cys auristatin E derivate, where affibody used capable binding human epidermal growth factor receptor 2 (HER2). Such a nanodrug not only increased blood time, but also enhanced tumor targeting capacity (abundant arms on surface) and accumulation tumor. result, this affibody-based showed excellent antitumor activity HER2-positive ovary breast models, nearly eradicated both solid tumors (about 100 mm3) large established (exceed 500 mm3). The relative proliferation inhibition ratio reaches 99.8% models.